Nanoparticles made of multi-block copolymer of lactic acid and ethylene glycol containing periodic side-chain carboxyl groups for oral delivery of cyclosporine A

Journal of the Royal Society Interface

Volumn 7, Issue SUPPL. 4, 2010, Pages

  Ankola, D D ^a   Battisti, A ^b   Solaro, R ^b   Kumar, M N V Ravi ^a  

^a UNIVERSITY OF STRATHCLYDE   (United Kingdom)

^b UNIVERSITY OF PISA   (Italy)

Author keywords

Drug delivery; Nanoparticles; Pharmacokinetics; Polymer

Indexed keywords

BIOCHEMISTRY; BLOCK COPOLYMERS; BODY FLUIDS; COPOLYMERIZATION; EMULSIFICATION; ETHYLENE; ETHYLENE GLYCOL; HYDROPHOBICITY; LACTIC ACID; MOLECULAR WEIGHT; NANOPARTICLES; ORGANIC ACIDS; PHARMACOKINETICS; POLYMERS;

CARBOXYL GROUPS; CYCLOSPORINE A; ENTRAPMENT EFFICIENCY; EVAPORATION PROCESS; HIGH MOLECULAR WEIGHT; HYDROPHILIC POLYMERS; HYDROPHOBIC DRUG; IN-VITRO; IN-VIVO; LOW MOLECULAR WEIGHT; NANOPARTICULATES; ORAL DELIVERY; POLY-LACTIDE-CO-GLYCOLIDE; SIDE-CHAIN; TISSUE LEVELS;

CONTROLLED DRUG DELIVERY;

CARBOXYL GROUP; COPOLYMER; CYCLOSPORIN A; NANOPARTICLE; POLY(LACTIC ACID CO ETHYLENE GLYCOL); POLYGLACTIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; DIFFUSION; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG RELEASE; EVAPORATION; FEASIBILITY STUDY; HYDROPHOBICITY; IN VITRO STUDY; IN VIVO STUDY; MALE; MOLECULAR WEIGHT; NONHUMAN; PARTICLE SIZE; RAT; TISSUE LEVEL;

RATTUS;

EID: 77955758519     PISSN: 17425689     EISSN: 17425662     Source Type: Journal    
DOI: 10.1098/rsif.2010.0046.focus     Document Type: Article

References (33)

1. Anderson, J. M. & Shive, M. S. 1997 Biodegradation and biocompatibility of PLA and PLGA microspheres. Adv. Drug Del. Rev. 28, 5-24. (doi:10.1016/S0169-409X(97)00048-3)
2. Ankola, D. D., Kumar, M. N. V. R., Chiellini, F. & Solaro, R. 2009 Multiblock copolymers of lactic acid and ethylene glycol containing periodic side-chain carboxyl groups: synthesis, characterization and nanoparticle preparation. Macromolecules 42, 7388-7395. (doi:10.1021/ma9012253)
3. Ankola, D. D., Durbin, E. W., Buxton, G. A., Schäfer, J., Bakowsky, U. & Kumar, M. N. V. R. 2010 Preparation, characterization and in silico modeling of biodegradable nanoparticles containing Cyclosporine A and Coenzyme Q10. Nanotechnology 21, 065104. (doi:10.1088/0957-4484/21/6/065104)
4. Bala, I., Hariharan, S. & Kumar, M. N. V. R. 2004 PLGA nanoparticles in drug delivery: the state of the art. Crit. Rev. Ther. Drug Carrier Syst. 21, 387-422. (doi:10.1615/CritRevTherDrugCarrierSyst.v21.i5.20)
5. Cecka, J. M. & Terasaki, P. I. 1991 The UNOS Scientific Renal Transplant Registry. Clin. Transpl. 1-11.
6. Cerbai, B., Solaro, R. & Chiellini, E. 2008 Synthesis and characterization of functional polyesters tailored for biomedical applications. J. Polym. Sci. A: Polym. Chem. 46, 2459-2476. (doi:10.1002/pola.22579)
7. Dai, J., Nagai, T., Wang, X., Zhang, T., Meng, M. & Zhang, Q. 2004 pH-sensitive nanoparticles for improving the oral bioavailability of cyclosporine A. Int. J. Pharm. 280, 229-240. (doi:10.1016/j.ijpharm.2004.05.006)
8. David-Neto, E., Lemos, F. B. C., Furusawa, E. A., Schwartzman, B. S., Cavalcante, J. S., Yagyu, E. M., Romano, P. & Ianhez, L. E. 2000 Impact of cyclosporin A pharmacokinetics on the presence of side effects in pediatric renal transplantation. J. Am. Soc. Nephrol. 11, 343-349.
9. Desai, S. J., Singh, P., Simonelli, A. P. & Higuchi, W. I. 1966 Investigation of factors influencing release of solid drug dispersed in wax matrices. III. Quantitative studies involving polyethylene plastic matrix. J. Pharm. Sci. 55, 1230-1234. (doi:10.1002/jps.2600551113)
10. Faulds, D., Goa, K. L. & Benfield, P. 1993 Cyclosporin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders. Drugs 45, 953-1040. (doi:10.2165/00003495-199345060- 00007)
11. max) correlate with freedom from liver graft rejection: results of a prospective, randomized comparison of Neoral and Sandimmune for liver transplantation (NOF-8)1,2. Transplantation 67, 1133-1137. (doi:10.1097/ 00007890-199904270-00008)
12. Gref, R., Quellec, P., Sanchez, A., Calvo, P., Dellacherie, E. & Alonso, M. J. 2001 Development and characterization of CyA-loaded poly(lactic acid)-poly(ethylene glycol)PEG micro- and nanoparticles. Comparison with conventional PLA particulate carriers. Eur. J. Biopharm. Pharm. 51, 111-118. (doi:10.1016/S0939-6411(00)00143-0)
13. Higuchi, T. 1963 Mechanism of sustained action medication, theoretical analysis of rate of release of solid drugs dispersed in solid matrices. J. Pharm. Sci. 52, 1145-1149.
14. Hixson, A. W. & Crowell, J. H. 1931 Dependence of reaction velocity upon surface and agitation: I-Theoretical consideration. Ind. Eng. Chem. 23, 923-931. (doi:10.1021/ie50260a018)
15. Italia, J. L., Bhardwaj, V. & Kumar, M. N. V. R. 2006 Disease, destination, dose and delivery aspects of cyclosporine: the state of the art. Drug Discov. Today 11, 846-854. (doi:10.1016/j.drudis.2006.07.015)
16. Italia, J. L., Bhatt, D. K., Bhardwaj, V., Tikoo, K. & Kumar, M. N. V. R. 2007 PLGA nanoparticles for oral delivery of cyclosporine: nephrotoxicity and pharmacokinetic studies in comparison to Sandimmune Neoral. J. Control. Rel. 119, 197-206. (doi:10.1016/j.jconrel.2007.02.004)
17. Kahan, B. D., Dunn, J., Fitts, C., Van Buren, D., Wombolt, D., Pollak, R., Carson, R., Alexander, J. W. & Choc, M. 1995 Reduced inter- and intra-subject variability in cyclosporine pharmacokinetics in renal transplant recipients treated with a microemulsion formulation in conjunction with fasting, low-fat meals, or high-fat meals 1, 2. Transplantation 59, 505-511.
18. Korsmeyer, R. W., Gurny, R., Doelker, E. M., Buri, P. & Peppas, N. A. 1983 Mechanism of solute release from porous hydrophilic polymers. Int. J. Pharm. 15, 25-35. (doi:10.1016/0378-5173(83)90064-9)
19. Lindholm, A. & Kahan, B. D. 1993 Influence of cyclosporine pharmacokinetics, trough concentrations, and AUC monitoring on outcome after kidney transplantation. Clin. Pharmacol. Ther. 54, 205-218.
20. Mittal, G., Sahana, D. K., Bhardwaj, V. & Kumar, M. N. V. R. 2007 Estradiol loaded PLGA nanoparticles for oral administration: effect of polymer molecular weight and copolymer composition on release behavior in vitro and in vivo. J. Control. Rel. 119, 77-85. (doi:10.1016/j.jconrel.2007.01.016)
21. Mohamed, F. & Van der Walle, C. F. 2008 Engineering biodegradable polyester particles with specific drug targeting and drug release properties. J. Pharm. Sci. 97, 71-87. (doi:10.1002/jps.21082)
22. Mueller, E. A., Kovarik, J. M., van Bree, J. B., Tetzloff, W., Grevel, J. & Kutz, K. 1994 Improved dose linearity of cyclosporine pharmacokinetics from a microemulsion formulation. Pharm. Res. 11, 301-304. (doi:10.1023/A: 1018923912135)
23. Najib, N. & Suleiman, M. 1985 The kinetics of drug release from ethyl cellulose solid dispersions. Drug Dev. Ind. Pharm. 11, 2169-2181. (doi:10.3109/03639048509087779)
24. Perico, N., Ruggenenti, P., Gaspari, F., Mosconi, L., Benigni, A., Amuchastegui, C. S., Gasparini, F. & Remuzzi, G. 1992 Daily renal hypoperfusion induced by cyclosporine in patients with renal transplantation. Transplantation 54, 56-60.
25. Polson, R. J., Powel-Jackson, P. R. & Williams, R. 1985 Convulsion associated with cyclosporine A in renal transplant recipients. Br. Med. J. 290, 1003-1010. (doi:10.1136/bmj.290.6473.1003-a)
26. Rezzani, R. 2004 Cyclosporine A and adverse effects on organs: histochemical studies. Prog. Histochem. Cytochem. 39, 85-128. (doi:10.1016/j.proghi.2004.04.001)
27. Sahana, D. K., Mittal, G., Bhardwaj, V. & Kumar, M. N. V. R. 2008 PLGA nanoparticles for oral delivery of hydrophobic drugs: influence of organic solvent on nanoparticle formation and release behavior in vitro and in vivo using estradiol as a model drug. J. Pharm. Sci. 97, 1530-1542. (doi:10.1002/jps.21158)
28. Signori, F., Chiellini, F. & Solaro, R. 2005 New self-assembling biocompatible-biodegradable amphiphilic. Polymer 46, 9642-9652. (doi:10.1016/j.polymer.2005.07.071)
29. Textor, S. C., Canzanello, V. J. & Taler, S. J. 1994 Cyclosporine-induced hypertension after transplantation. Mayo Clin. Proc. 69, 1182-1193.
30. Tobio, M., Sanchez, A., Vila, A., Soriano, I., Evora, C., Vila-Jato, J. L. & Alonso, M. J. 2000 The role of PEG on the stability in digestive fluids and in vivo fate of PEG-PLA nanoparticles following oral administration. Colloids Surf. B: Biointerf. 18, 315-323. (doi:10.1016/S0927-7765(99)00157-5)
31. Tracy, M., Ward, K., Firouzabadian, L., Wang, Y., Dong, N., Qian, R. & Zhang, Y. 1999 Factors affecting the degradation rate of poly(lactide-co-glycolide) microspheres in vivo and in vitro. Biomaterials 20, 1057-1062. (doi:10.1016/S0142-9612(99)00002-2)
32. Varela, M. C., Guzman, M., Molpeceres, J., del Rosario Aberturas, M., Rodriguez-Puyol, D. & Rodriguez-Puyol, M. 2001 Cyclosporine-loaded polycaprolactone nanoparticles: immunosuppression and nephrotoxicity in rats. Eur. J. Pharm. Sci. 12, 471-478.
33. Yenice, I., Mocan, M. C., Palaska, E., Bochot, A., Bilensoy, E., Vural, I., Irkeç, M. & Hincal, A. A. 2008 Hyaluronic acid coated poly-3-caprolactone nanospheres deliver high concentrations of cyclosporine A into the cornea. Exp. Eye Res. 87, 162-167. (doi:10.1016/j.exer.2008.04.002)